These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 21684677

  • 1. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C.
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [Abstract] [Full Text] [Related]

  • 2. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [Abstract] [Full Text] [Related]

  • 3. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [Abstract] [Full Text] [Related]

  • 4. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R.
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [Abstract] [Full Text] [Related]

  • 5. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
    Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L.
    Neurourol Urodyn; 2011 Mar; 30(3):292-301. PubMed ID: 21284024
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
    Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E.
    J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
    [Abstract] [Full Text] [Related]

  • 7. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS.
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [Abstract] [Full Text] [Related]

  • 8. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H, Zong H, Cui Y, Li N, Zhang Y.
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS.
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [Abstract] [Full Text] [Related]

  • 10. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M, Rosenberg MT, Perelman MA.
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [Abstract] [Full Text] [Related]

  • 11. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ, Gales MA.
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [Abstract] [Full Text] [Related]

  • 12. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC.
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [Abstract] [Full Text] [Related]

  • 13. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
    Wang C.
    Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
    [Abstract] [Full Text] [Related]

  • 15. Lower urinary tract symptoms and sexual dysfunction: a common approach.
    Giuliano F.
    BJU Int; 2008 Mar; 101 Suppl 3():22-6. PubMed ID: 18307682
    [Abstract] [Full Text] [Related]

  • 16. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 17. Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management.
    Orabi H, Albersen M, Lue TF.
    Int J Impot Res; 2011 Dec; 23(3):99-108. PubMed ID: 21593760
    [Abstract] [Full Text] [Related]

  • 18. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F.
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
    Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY.
    Int J Impot Res; 2009 Jul; 21(2):122-8. PubMed ID: 19194451
    [Abstract] [Full Text] [Related]

  • 20. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA, Gonzalez RR, Te AE.
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.